Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.56 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.48 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162978 | 1.00 | KAT2B (0.56) | KAT2BCARM1PRMT6CHRNB2CHRNA7 | |
| SCHEMBL4443892 | 1.00 | KAT2B (0.56) | KAT2BCARM1PRMT6CHRNB2CHRNA7 | |
| SCHEMBL2267302 | 0.84 | CHRNB2 (0.50) | KAT2BCHRNB2CHRNA7CHRNA4CHRNB4 | |
| SCHEMBL2267304 | 0.84 | CHRNB2 (0.50) | KAT2BCHRNB2CHRNA7CHRNA4CHRNB4 | |
| SCHEMBL14626061 | 0.81 | RAB9A (0.51) | CARM1PRMT6 | |
| SCHEMBL18685000 | 0.80 | CASP3 (0.43) | KAT2BCARM1PRMT6CHRNB2CHRNA7 | |
| SCHEMBL5378500 | 0.80 | CASP3 (0.43) | KAT2BCARM1PRMT6 | |
| SCHEMBL30969256 | 0.78 | KAT2B (0.45) | KAT2BCHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL8055430 | 0.78 | EPHX1 (0.58) | CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL13220244 | 0.78 | CXCR4 (0.50) | KAT2BCHRNB2CHRNA7CHRNA4CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | OSI PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | claimed |
| US-20080153822-A1 | Methods of treating pain | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| WO-2005012262-A1 | 2-AMINOPHENYL-4-PHENYLPYRIMIDINES AS KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | OSI PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021419-A1 | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | GRK3, NCOR1, GRM3 | KAT2B 592/4885CARM1 273/4885PRMT6 276/4885 |
| US-20030139427-A1 | Bicyclic pyrimidinyl derivatives and methods of use thereof | ADORA2A, ADORA3, ADORA1 | KAT2B 4681/4885CARM1 4042/4885PRMT6 3134/4885 |
| US-20080153822-A1 | Methods of treating pain | OPRL1, ACHE, OPRK1 | KAT2B 661/4885CARM1 3449/4885PRMT6 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.